Meridian Bioscience Inc (VIVO) Earnings Report, Financial Results, Financial analysis

Meridian Bioscience Inc reported in the first quarter of 2023 net loss per share of $-0.68 compare to earnings per share of $0.15 in the same quarter a year ago a decrease compare to $-0.16 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.68	$ 57 Mill
$-0.83	$-19M -25.33 %

Meridian Bioscience Inc 's Revenue fell by -25.33 % in first quarter of 2023 (Dec 31 2022) year on year, to $57 million and declined by -16.04 % sequentially.

Meridian Bioscience Inc is Expected to report next financial results on August 04, 2023.

More on VIVO's Income Statement

VIVO's NET INCOME

Meridian Bioscience Inc 's in thefirst quarter of 2023 recorded net loss of $-29.821 million, compare to net income of $6.657 million achieved in IV. Quarter a year ago.

Sequentially net loss advanced

More on VIVO's Growth

Meridian Bioscience Inc Inventories
Inventories declined by -5.44 % to $72.66 million from IV. Quarter a year ago, sequentially inventories rose by 3.65 %. In Dec 31 2022 company's net cash and cash equivalents decreased by $-7 million, capital expenditures fell by 39.32%, to $-3 millions compare to same quarter a year ago and fell by 35.48% from III. Quarter (Jun 30 2022).

More on VIVO's Cash flow Statement

Earnings quality

Meridian Bioscience Inc does not pay out common stock dividend.

In trailing twelve-month period Meridian Bioscience Inc earned $ 1.78 cash per share, on a free-cash flow basis 1110.94 % of net earning per share.

Book value fell by -5.61 % sequentially to $7.76 per share.
Tangible Book value fell to $ 3.38 per share from $ 3.86.

Company repurchased 0.58 million shares or 1.30 % in Dec 31 2022.
Interest Coverage Ratio was 19.43. Debt Coverage Ratio was 0.69.

• More on VIVO's Dividends

Market Capitalization (Millions)	1,491
Shares Outstanding (Millions)	44
Total Debt (Millions $)	25
Revenue (TTM) (Millions $)	324
Net Income (TTM) (Millions $)	7
Cash Flow (TTM) (Millions $)	26
Capital Exp. (TTM) (Millions $)	-8
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	850

Earnings quality

Meridian Bioscience Inc does not pay out common stock dividend.

In trailing twelve-month period Meridian Bioscience Inc had $ 1.78 cash flow per share, on a free-cash flow basis 1110.94 % of net earning per share.

Book value fell by -5.61 % sequentially to $7.76 per share.
Tangible Book value fell to $ 3.38 per share from $ 3.86.

Company repurchased 0.58 million shares or 1.30 % in Dec 31 2022.
Interest Coverage Ratio was 19.43. Debt Coverage Ratio was 0.69.

• More on VIVO's Balance Sheets

Market Capitalization (Millions)	1,491
Shares Outstanding (Millions)	44
Total Debt (Millions $)	25
Revenue (TTM) (Millions $)	324
Net Income (TTM) (Millions $)	7
Cash Flow (TTM) (Millions $)	26
Capital Exp. (TTM) (Millions $)	-8
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	850

Meridian Bioscience Inc

VIVO's Financial Statements and Analysis